TERN RSI Chart
Last 7 days
4.6%
Last 30 days
-26.0%
Last 90 days
-10.5%
Trailing 12 Months
-62.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 4.7M | 0 | 0 | 12.9M |
2022 | 228.0K | 387.0K | 837.0K | 2.1M |
2021 | 0 | 118.0K | 117.0K | 170.0K |
2020 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 03, 2024 | vivo opportunity, llc | sold | -25,723 | 6.2 | -4,149 | - |
Apr 03, 2024 | vivo opportunity, llc | sold | -643,994 | 6.2 | -103,870 | - |
Apr 03, 2024 | vivo opportunity, llc | sold | -186,291 | 6.2 | -30,047 | - |
Apr 02, 2024 | vivo opportunity, llc | sold | -146,859 | 6.65 | -22,084 | - |
Apr 02, 2024 | vivo opportunity, llc | sold | -20,282 | 6.65 | -3,050 | - |
Apr 02, 2024 | vivo opportunity, llc | sold | -507,701 | 6.65 | -76,346 | - |
Apr 01, 2024 | vivo opportunity, llc | sold | -275,483 | 6.99 | -39,411 | - |
Apr 01, 2024 | vivo opportunity, llc | sold | -38,102 | 6.99 | -5,451 | - |
Apr 01, 2024 | vivo opportunity, llc | sold | -952,422 | 6.99 | -136,255 | - |
Jan 23, 2024 | quirk erin | acquired | - | - | 75,000 | president, head of r&d |
Which funds bought or sold TERN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 23, 2024 | AMALGAMATED BANK | reduced | -72.61 | -25,000 | 9,000 | -% |
Apr 22, 2024 | Vivo Capital, LLC | unchanged | - | 466,060 | 43,676,400 | 3.43% |
Apr 22, 2024 | MetLife Investment Management, LLC | unchanged | - | 33,744 | 149,997 | -% |
Apr 19, 2024 | ZRC WEALTH MANAGEMENT, LLC | new | - | 1,476 | 1,476 | -% |
Apr 18, 2024 | Capital Advisors, Ltd. LLC | unchanged | - | - | 1,000 | -% |
Apr 11, 2024 | Fortitude Family Office, LLC | sold off | -100 | -1,947 | - | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 613 | 5,991 | 6,737 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 52.00 | 52.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -0.66 | 3,120,050 | 14,196,700 | -% |
Mar 08, 2024 | ICA Group Wealth Management, LLC | new | - | 519 | 519 | -% |
Unveiling Terns Pharmaceuticals, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Terns Pharmaceuticals, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.6B | 6.8B | -8.82 | 6.07 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.14 | 9.91 | ||||
BMRN | 17.2B | 2.4B | 102.64 | 7.11 | ||||
INCY | 11.6B | 3.7B | 19.44 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.39 | 15.18 | ||||
BBIO | 4.4B | - | -6.74 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.09 | 12.46 | ||||
ARWR | 2.9B | 240.7M | -9.72 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -44.6 | 3.76 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.96 | 4.48 | ||||
NVAX | 580.8M | 983.7M | -1.07 | 0.59 | ||||
CRBP | 372.9M | 881.7K | -8.36 | 466.16 | ||||
INO | 237.4M | 4.9M | -1.76 | 48.79 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Terns Pharmaceuticals, Inc. News
Income Statement (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q2 | 2020Q1 |
Revenue | -100.0% | - | 2,693,000 | 1,328,000 | 499,000 | 214,000 | 69,000 | 55,000 | 49,000 | 55,000 | 11,000 | 2,000 | 50,000 |
Costs and Expenses | -0.4% | 24,058,000 | 24,157,000 | 16,828,000 | 17,292,000 | 14,084,000 | 13,825,000 | 14,878,000 | 11,868,000 | 10,818,000 | 13,296,000 | 10,097,000 | 9,423,000 |
S&GA Expenses | -7.1% | 6,599,000 | 7,101,000 | 6,170,000 | 5,131,000 | 5,422,000 | 5,689,000 | 5,416,000 | 4,715,000 | 4,857,000 | 4,561,000 | 2,486,000 | 2,179,000 |
EBITDA Margin | 51.1% | -6.95 | -14.21 | -28.20 | -69.05 | -136 | -217 | -289 | -380 | -374 | - | - | - |
Income Taxes | -18.3% | 49,000 | 60,000 | 318,000 | 13,000 | 6,000 | 21,000 | 435,000 | 20,000 | 14,000 | 39,000 | - | - |
Earnings Before Taxes | 2.3% | -20,970,000 | -21,468,000 | -15,504,000 | -16,807,000 | -13,924,000 | -13,752,000 | -13,813,000 | -11,815,000 | -10,724,000 | -13,298,000 | -9,845,000 | -9,206,000 |
EBT Margin | 51.2% | -6.97 | -14.30 | -28.43 | -69.65 | -137 | -219 | -292 | -385 | -379 | - | - | - |
Net Income | 2.4% | -21,019,000 | -21,528,000 | -15,822,000 | -16,820,000 | -13,930,000 | -13,773,000 | -14,248,000 | -11,835,000 | -10,738,000 | -13,337,000 | -9,688,000 | -9,001,000 |
Net Income Margin | 51.4% | -6.99 | -14.39 | -28.60 | -70.22 | -138 | -221 | -295 | -391 | -385 | - | - | - |
Free Cashflow | -34.6% | -19,360,000 | -14,382,000 | -11,245,000 | -13,428,000 | -11,169,000 | -13,542,000 | -10,869,000 | -8,156,000 | -8,802,000 | -14,340,000 | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -1.2% | 269 | 272 | 290 | 301 | 287 | 193 | 145 | 157 | 168 | 180 | 188 | 199 | 92.00 |
Current Assets | -1.1% | 267 | 270 | 288 | 300 | 285 | 191 | 143 | 154 | 167 | 179 | 187 | 198 | 91.00 |
Cash Equivalents | 110.9% | 80.00 | 38.00 | 81.00 | 184 | 143 | 63.00 | 17.00 | 44.00 | 48.00 | 65.00 | 68.00 | 99.00 | 75.00 |
Net PPE | -3.8% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -0.8% | 13.00 | 13.00 | 16.00 | 14.00 | 10.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 9.00 | 24.00 |
Current Liabilities | -1.2% | 12.00 | 12.00 | 14.00 | 12.00 | 8.00 | 7.00 | 6.00 | 6.00 | 7.00 | 7.00 | 6.00 | 8.00 | 23.00 |
Shareholder's Equity | -1.2% | 255 | 258 | 274 | 288 | 277 | 184 | 137 | 149 | 160 | 172 | 181 | 190 | - |
Retained Earnings | -6.7% | -332 | -311 | -281 | -263 | -242 | -226 | -209 | -195 | -182 | -167 | -155 | -145 | -131 |
Additional Paid-In Capital | 3.0% | 588 | 571 | 557 | 552 | 520 | 412 | 348 | 345 | 343 | 340 | 337 | 335 | 15.00 |
Shares Outstanding | 4.5% | 65.00 | 62.00 | 61.00 | 57.00 | 54.00 | 30.00 | 25.00 | 25.00 | 25.00 | 22.00 | 20.00 | 15.00 | - |
Float | - | - | - | 409 | - | - | - | 47.00 | - | - | - | 225 | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | 6.7% | -19,316 | -20,699 | -12,993 | -14,382 | -11,211 | -13,436 | -11,162 | -13,300 | -10,669 | -8,082 | -8,760 | -14,316 | -7,387 | -6,313 | -8,822 | -7,287 |
Share Based Compensation | -76.7% | 3,282 | 14,083 | 4,233 | 3,938 | 2,687 | 2,686 | 2,651 | 2,744 | 2,550 | 1,855 | 1,909 | 1,832 | 786 | 513 | 190 | 202 |
Cashflow From Investing | 311.7% | 47,232 | -22,313 | -90,837 | 27,931 | -14,546 | -1,240 | -15,974 | 9,488 | -6,421 | 4,443 | -20,902 | -96,816 | -47.00 | -5.00 | -102 | 6,847 |
Cashflow From Financing | 69210.0% | 13,862 | 20.00 | 489 | 27,580 | 105,970 | 61,001 | 124 | - | 16.00 | 797 | -1,589 | 135,169 | 68,640 | 32.00 | 16,876 | -33.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 63,497 | $ 39,617 |
General and administrative | 39,061 | 22,412 |
Total operating expenses | 102,558 | 62,029 |
Loss from operations | (102,558) | (62,029) |
Other income | ||
Interest income | 12,901 | 2,110 |
Other expense, net | (314) | (68) |
Total other income, net | 12,587 | 2,042 |
Loss before income taxes | (89,971) | (59,987) |
Income tax expense | (239) | (358) |
Net loss | $ (90,210) | $ (60,345) |
Net loss per share, basic | $ (1.27) | $ (1.67) |
Net loss per share, diluted | $ (1.27) | $ (1.67) |
Weighted average common stock outstanding, basic | 71,259,239 | 36,033,045 |
Weighted average common stock outstanding, diluted | 71,259,239 | 36,033,045 |
Other comprehensive loss: | ||
Net loss | $ (90,210) | $ (60,345) |
Unrealized gain (loss) on available-for-sale securities, net of tax | 671 | (320) |
Foreign exchange translation adjustment, net of tax | 132 | (164) |
Comprehensive loss | $ (89,407) | $ (60,829) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 79,926 | $ 143,235 |
Marketable securities | 183,514 | 139,879 |
Prepaid expenses and other current assets | 3,992 | 2,071 |
Total current assets | 267,432 | 285,185 |
Property and equipment, net | 506 | 757 |
Operating lease assets | 523 | 1,047 |
Other assets | 56 | 37 |
Total assets | 268,517 | 287,026 |
Current liabilities: | ||
Accounts payable | 2,515 | 1,645 |
Accrued expenses and other current liabilities | 8,826 | 6,162 |
Current portion of operating lease liabilities | 603 | 661 |
Total current liabilities | 11,944 | 8,468 |
Taxes payable, non-current | 1,206 | 1,071 |
Operating lease liabilities, non-current | 0 | 544 |
Total liabilities | 13,150 | 10,083 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value, 150,000,000 shares authorized at December 31, 2023 and 2022; 64,576,719 and 53,723,171 shares issued and outstanding at December 31, 2023 and 2022, respectively | 6 | 5 |
Additional paid-in capital | 588,008 | 520,178 |
Accumulated other comprehensive loss | (19) | (822) |
Accumulated deficit | (332,628) | (242,418) |
Total stockholders' equity | 255,367 | 276,943 |
Total liabilities and stockholders' equity | $ 268,517 | $ 287,026 |
 | ternspharma.com |
---|---|
 | Biotechnology |
 | 46 |